-
Sacubitril inhibits neprilysin
- Sacubitril is a prodrug, converted to the active metabolite sacubitrilat (LBQ657).
- Neprilysin normally breaks down natriuretic peptides such as ANP, BNP, and CNP.
- Its inhibition increases these peptides, leading to:
- Vasodilation
- Increased sodium and water excretion (natriuresis and diuresis)
- Reduced aldosterone activity
- Reduced cardiac preload and afterload
- Less myocardial hypertrophy and fibrosis
-
Valsartan blocks angiotensin-II AT1 receptors
- It prevents angiotensin II mediated vasoconstriction, sodium retention, aldosterone release, sympathetic activation, and adverse cardiac remodeling.
- This is necessary because neprilysin also metabolizes angiotensin II. Neprilysin inhibition alone could therefore increase angiotensin II activity.
Net effect: ARNI enhances the beneficial natriuretic peptide system while blocking the harmful renin-angiotensin-aldosterone system. This reduces congestion and cardiac remodeling and improves outcomes in heart failure with reduced ejection fraction.
FDA prescribing information